Seeking Alpha
 

Zoetis (ZTS)

- NYSE
  • Tue, May 5, 9:45 AM
    • Zoetis (ZTS +2.4%) Q1 results: Revenues: $1,102M (+0.5%), Livestock: $715M (+1.3%), Companion Animal: $377M (-0.8%), Contract Manufacturing: $10M (-9.1%); COGS: $394M (+4.0%); R&D Expense: $80M (-8.0%); SG&A: $354M (-0.6%); Net Income: $165M (+6.5%); EPS: $0.33 (+6.5%).
    • 2015 Guidance: Revenue: $4,675M - 4,775M from $4,800M - 4,900M; Adjusted SG&A Expenses: $1,355M - 1,405M from $1,420M - 1,470M; Adjusted R&D Expenses: $380M - 400M from $385M - 405M; Adjusted interest expense and other (income)/deductions: ~110M (unch); Adjusted diluted EPS: $1.61 - 1.68 (unch); Adjusted net income: $810M - 845M (unch); Reported diluted EPS: $0.79 - 1.02 from $1.32 - 1.39; Reported net income: $400M - 515M.
    • 2016 Guidance: Revenue: $4,650M - 4,800M; Adjusted SG&A Expenses: $1,270M - 1,340M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $1.81 - 1.93; Adjusted net income: $910M - 970M; Reported EPS: $1.45 - 1.65; Reported net income: $730M - 830M.
    • 2017 Guidance: Revenue: $4,850M - 5,050M; Adjusted SG&A Expenses: $1,240M - 1,330M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $2.18 - 2.32; Adjusted net income: $1,095M - 1,165M; Reported EPS: $1.98 - 2.16; Reported net income: $995M - 1,085M.
    | Comment!
  • Tue, May 5, 7:02 AM
    • Zoetis (NYSE:ZTS): Q1 EPS of $0.41 beats by $0.04.
    • Revenue of $1.1B (flat Y/Y) misses by $10M.
    • Press Release
    | Comment!
  • Tue, Mar. 31, 1:42 PM
    • Even after his big win with Allergan, Bill Ackman's Pershing Square maintains significant exposure (~50%) to the healthcare sector. In a recent regulatory filing, Pershing disclosed a 19.5M share stake in Valeant Pharmaceuticals (VRX -0.2%) valued at ~$3.83B, making it the largest position in its equity portfolio. It also has a 41.8M share stake in Zoetis (ZTS -0.2%) valued at almost $2B.
    • In case you were wondering, Pershing is also maintaining its short position in Herbalife (HLF -0.9%).
    | 4 Comments
  • Fri, Feb. 27, 4:12 PM
    | Comment!
  • Wed, Feb. 11, 8:02 AM
    • Zoetis (NYSE:ZTS) Q4 results ($M): Revenues: 1,320 (+5.3%); Livestock: 904 (+7.1%); Companion Animal: 405 (+2.8%); Operating Expenses: 621 (+7.3%); Net Income: 126 (+20.0%); EPS: 0.25 (+19.0%).
    • 2015 Guidance: Revenues: $4.8B - 4.9B; Non-GAAP Net Income: $810M - 845M; EPS: $1.32 - 1.39; Non-GAAP EPS: $1.61 - 1.68.
    | 1 Comment
  • Wed, Feb. 11, 7:02 AM
    • Zoetis (NYSE:ZTS): Q4 EPS of $0.40 beats by $0.04.
    • Revenue of $1.32B (+5.6% Y/Y) beats by $50M.
    • Press Release
    | Comment!
  • Tue, Feb. 10, 5:30 PM
  • Tue, Feb. 10, 4:41 PM
    • Zoetis (NYSE:ZTS) finalizes its purchase of Abbott's animal health assets for $255M. The integration of the business into its operations is expected to impact this year's performance as follows:
    • Additional revenue: ~$75M; a negative impact on reported EPS of ($0.03); a positive impact of $0.01 on non-GAAP EPS.
    • Previously: Zoetis buys Abbott's animal health business (Nov. 17, 2014)
    | Comment!
  • Wed, Feb. 4, 9:20 AM
    • Zoetis (NYSE:ZTS) adds Pershing Square's William F. Doyle to the Board of Directors effective February 3. The Board also agrees to add another director that is mutually acceptable to both the company and Pershing.
    • Activist investor Pershing Square, headed by Bill Ackman, established a large stake (~10%) in the firm several months ago.
    • Previously: Ackman confirms Zoetis stake (Nov. 12, 2014)
    | 3 Comments
  • Dec. 31, 2014, 10:39 AM
    • Zoetis (ZTS +0.5%) will report Q4 and full-year results on February 11 before the open. The conference call will begin at 8:30 am ET.
    • Consensus views for Q4 and 2014 are EPS of $0.36 and $1.54 on revenues of $1.3B and $4.8B, respectively.
    | Comment!
  • Dec. 18, 2014, 7:23 AM
    • Zoetis (NYSE:ZTS) declares $0.08/share quarterly dividend, 15.3% increase from prior dividend of $0.07.
    • Forward yield 0.81%
    • Payable March 3; for shareholders of record Jan. 22; ex-div Jan. 20.
    | Comment!
  • Dec. 4, 2014, 7:24 AM
    • Thinly-traded nano cap Kindred Biosciences (NASDAQ:KIN) plummets 24% premarket on robust volume in response to its announcement that it is terminating its atopic dermatitis program, including its AtoKin study, in favor of more promising programs.
    • CEO Richard Chin says the main reason for the move is the rapid uptake of a recently-launched atopic dermatitis product that has raised the bar for future competitors. He doesn't believe AtoKin is differentiated enough to be a market leader.
    • Kindred has been in a down trend March. Shares have dropped almost 75% since the March 14 peak of $26.99.
    • BMO analyst Alex Arfaei says Kindred's decision is "incrementally positive" for Zoetis' (NYSE:ZTS) Apoquel, which could hit $300M in sales by 2019.
    | 2 Comments
  • Nov. 18, 2014, 1:51 PM
    • Using AstraZeneca's playbook, Zoetis (ZTS -0.3%) presents its plan to drive growth and create shareholder value in its first Investor Day event.
    • Three capabilities will drive growth: the firm's direct selling model, its customer-focused R&D and its robust high-quality supply chain.
    • 2015 Guidance: Revenues: $4.85B - 4.95B (6.5 - 8.5% operational growth); GAAP EPS: $1.36 - 1.43; non-GAAP EPS: $1.61 - 1.68.
    • Valeant should not expect a bargain if it decides to make a bid.
    • Previously: Zoetis could be fallback option for Valeant
    | 1 Comment
  • Nov. 18, 2014, 10:24 AM
    • Zoetis' (ZTS -1.5%) BOD authorizes a $500M stock repurchase program. Shares will be acquired at the discretion of management depending on market conditions and business needs.
    • The rather modest initiative may be the first sign that executives are sensing that Valeant Pharmaceuticals (VRX +4.2%) has the company in its crosshairs.
    • Previously: Ackman confirms Zoetis stake
    | 1 Comment
  • Nov. 17, 2014, 9:16 AM
    • Zoetis (NYSE:ZTS) acquires Abbott (NYSE:ABT) division Abbott Animal Health, a companion animal health business focused on the veterinary surgical suite, for $255M.
    • The transaction should close in Q1 2015.
    | Comment!
  • Nov. 12, 2014, 8:25 AM
    | 1 Comment
Visit Seeking Alpha's
ZTS vs. ETF Alternatives
Company Description
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.